Set As Homepage | Add Favourite | E-mail | Backstage | 中文版 | ENGLISH

  •  

        Your present location:Clinical project > MS Diagnosis
        Today’s Mass Spec
         
        The identification of specific biomarkers is essential for the realization of personalized medicine, in terms of better estimated disease risk, more adapted therapies and improved disease outcome. The next generation sequencing (NGS) has elevated molecular diagnosis to a new level. Through sequence comparison, nowadays researchers can identify unique gene defects from individual patients and provide these findings to clinicians for personalized medication.
         
        However, gene defects are not necessary to be converted into protein malformations and therefore they do not directly initiate diseases nor define the stage of diseases. Instead, proteins are more dynamic, diverse and more directly reflective of cellular physiology than gene markers, offering high potential to serve as biomarkers for routine clinical applications. 
         
        Traditionally, the measurement of protein biomarkers in clinical samples has primarily relied on antibody-based immunoassays. However, antibody-based methods are accompanied with several limitations in availability, automation, multiplexing and quantitation. The last decade has witnessed significant progress in protein identification and quantification using Mass Spec-based methods. In particular, new instrument configurations, new quantitative approaches and optimized software tools to analyze proteomic data have largely improved the analytical performance of Mass Spec-based proteomics, in terms of reproducibility, dynamic range, limit of detection, comprehensiveness and quality of the results.
         
         
        The acquisition of personalized proteomic expression maps containing multiple, ideally all detectable biomarker candidates would be highly desirable for molecular diagnoses, because it would allow the non-biased measurement of all possible biomarkers across sample cohorts, to maximize the predictive power and to select the biomarker or biomarker pattern with the best discriminant power. Taken above, ProteinT Biotech prioritized the effort of using state-of-the-art Mass Spec to develop proteomic diagnostic assays for a variety of clinical diseases.